{"id":41025,"date":"2021-08-01T06:28:07","date_gmt":"2021-08-01T06:28:07","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=41025"},"modified":"2021-08-01T10:18:23","modified_gmt":"2021-08-01T10:18:23","slug":"us-cdc-recommended-third-vaccine-dose-in-some-patients","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/41025","title":{"rendered":"US CDC recommends third vaccine dose in some groups"},"content":{"rendered":"<div>\n<p class=\"HTBsubhead2articletitle\"><strong><span lang=\"EN-US\"><img loading=\"lazy\" decoding=\"async\" class=\" alignright\" src=\"https:\/\/i-base.info\/wp-content\/uploads\/2020\/03\/COVID-19-graphic.png\" width=\"231\" height=\"142\" \/><\/span>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\"><strong>At a meeting on 22 July 2021 of the US\u00a0Advisory Committee on Immunization Practices (ACIP), a presentation from the US CDC recommended a third dose for some people who are immunocompromised. [1]<\/strong><\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">An excellent slide set compiling the available evidence is also available online. [2]<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">Based on 2013 data, the CDC estimates this group to be approximately 2.7% of the US adult population (roughly 5 to 6 million people).<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">This includes:<\/p>\n<\/div>\n<div>\n<ul>\n<li class=\"HTBBODYtext\"><span lang=\"EN-US\">Solid tumour and hematologic malignancies.<\/span><\/li>\n<li class=\"HTBBODYtext\">Receipt of solid-organ or hematopoietic stem cell transplant.<\/li>\n<li class=\"HTBBODYtext\">Severe primary immunodeficiencies.<\/li>\n<li class=\"HTBBODYtext\">People living with HIV.<\/li>\n<li class=\"HTBBODYtext\">Treatment with immunosuppressive medications. These include cancer drugs, TNF blockers, certain biologic agents (eg rituximab), and high-dose corticosteroids.<\/li>\n<\/ul>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">This is not proposing a third dose to the whole population.<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">Currently, many people who have received two doses assume protection when this might not be the case. These people are more likely to have breakthrough infections.<\/p>\n<\/div>\n<div>\n<ul>\n<li class=\"HTBBODYtext\"><span lang=\"EN-US\">44% of hospitalised breakthrough cases in the US are immunocompromised people.<\/span><\/li>\n<li class=\"HTBBODYtext\">40% of hospitalised breakthrough cases in Israel are immunocompromised people.<\/li>\n<\/ul>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">The recommendations are similar to earlier guidelines in France, Israel and the UK. [3, 4, 5]<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">The US FDA with also apparently need to either approval this off-label use or approve the third vaccine.<\/p>\n<\/div>\n<div>\n<p class=\"HTBBODYtext\">Pfizer announced plans to apply for an indication for three doses in July 2021. [6]<\/p>\n<\/div>\n<div>\n<p class=\"HTBreferences\"><span lang=\"EN-US\">References<\/span><\/p>\n<\/div>\n<div>\n<ol>\n<li class=\"HTBreferences\"><span lang=\"EN-US\">ACIP meeting (22 July 2021).<br \/>\n<\/span><a href=\"https:\/\/www.cdc.gov\/vaccines\/acip\">https:\/\/www.cdc.gov\/vaccines\/acip<\/a><\/li>\n<li class=\"HTBreferences\">Oliver S. Data and clinical considerations for additional doses in immunocompromised people.<br \/>\n<a href=\"https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2021-07-22.html\">https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2021-07-22.html<\/a> (slides page)<br \/>\n<a href=\"https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-07\/07-COVID-Oliver-508.pdf\">https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-07\/07-COVID-Oliver-508.pdf<\/a> (PDF slides)<\/li>\n<li class=\"HTBreferences\">France routinely recommends third dose of COVID-19 vaccine for some people with reduced immune function. HTB (1 June 2021).<br \/>\n<a href=\"https:\/\/i-base.info\/htb\/40634\">https:\/\/i-base.info\/htb\/40634<\/a><\/li>\n<li class=\"HTBreferences\">CNBC. Israel is offering a third Pfizer shot amid spiking cases, even as the U.S. says it\u2019s not yet needed. (13 July 2021)<br \/>\n<a href=\"https:\/\/www.cnbc.com\/2021\/07\/13\/israel-is-offering-a-third-pfizer-shot-amid-spiking-cases.html\">https:\/\/www.cnbc.com\/2021\/07\/13\/israel-is-offering-a-third-pfizer-shot-amid-spiking-cases.html<\/a><\/li>\n<li class=\"HTBreferences\">Plans for universal third vaccine dose for UK adults from September. HTB (1 July 2021).<br \/>\n<a href=\"https:\/\/i-base.info\/htb\/40892\">https:\/\/i-base.info\/htb\/40892<\/a><\/li>\n<li class=\"HTBreferences\">STAT news. Pfizer to seek FDA authorization for third, booster dose of its Covid-19 vaccine. (8 July 2021).<br \/>\n<a href=\"https:\/\/www.statnews.com\/2021\/07\/08\/pfizer-to-seek-fda-authorization-for-third-booster-dose-of-covid19-vaccine\/\">https:\/\/www.statnews.com\/2021\/07\/08\/pfizer-to-seek-fda-authorization-for-third-booster-dose-of-covid19-vaccine\/<\/a><\/li>\n<\/ol>\n<p><em>This report was frist published on 26 July 2021.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base At a meeting on 22 July 2021 of the US\u00a0Advisory Committee on Immunization Practices (ACIP), a presentation from the US CDC recommended a third dose for some people who are immunocompromised. [1] An excellent slide set &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[292,278],"tags":[],"class_list":["post-41025","post","type-post","status-publish","format-standard","hentry","category-covid-19-vaccine","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/41025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=41025"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/41025\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=41025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=41025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=41025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}